Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Melanoma 65Neoplasms 29Neoplasm Metastasis 11Thyroid Neoplasms 10Thyroid Carcinoma, Anaplastic 9Glioma 9Brain Neoplasms 9Multiple Myeloma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Hematologic Neoplasms 6Thyroid Cancer, Papillary 4Skin Neoplasms 4Ameloblastoma 4Histiocytosis, Langerhans-Cell 3Glioblastoma 3Astrocytoma 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Ganglioneuroma 2

Interventions

pembrolizumab 3Paclitaxel 2relatlimab 1nintedanib 1lifileucel 1dabrafenib 1Vitamin D 1Temozolomide 1Surveys and Questionnaires 1Opdualag 1Nivolumab 1Ipilimumab 1Eye Movement Desensitization Reprocessing 1Electrochemotherapy 1Dacarbazine 1Cholecalciferol 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma, Cutaneous Malignant × dabrafenib × Clear all
NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Immuneering Corporation

Phase 1/2 Active not recruiting
209 enrolled
DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡